Passage BIO, Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended September 30, · · Nine Months Ended September 30, | ||||||||||||
| (in thousands, except share and per share data) · 2025 · 2024 · · 2025 · 2024 | ||||||||||||
| Operating expenses: · · · · · | ||||||||||||
| Research and development | | $4,307 | | $8,656 | | $17,858 | | $30,621 | ||||
| General and administrative | | 4,348 | | 7,251 | | 14,953 | | 20,276 | ||||
| Impairment of long-lived assets | | | — | | | 4,795 | | | 2,637 | | | 5,233 |
| Loss from operations | | (8,655) | | (20,702) | | (35,448) | | (56,130) | ||||
| Other income (expense), net | | 906 | | 1,362 | | 2,909 | | 4,088 | ||||
| Net loss | | $(7,749) | | $(19,340) | | $(32,539) | | $(52,042) | ||||
| Per share information: | | | | | | |||||||
| Net loss per share of common stock, basic and diluted | | $(2.44) | | $(6.15) | | $(10.26) | | $(17.04) | ||||
| Weighted average common shares outstanding, basic and diluted | | 3,178,710 | | 3,146,582 | | 3,170,573 | | 3,054,440 | ||||
| Comprehensive loss: | | | | | | | | | | | | |
| Net loss | | $(7,749) | | $(19,340) | | $(32,539) | | $(52,042) | ||||
| Unrealized gain (loss) on marketable securities | | | — | | | 99 | | | (8) | | | 75 |
| Comprehensive loss | | $(7,749) | | $(19,241) | | $(32,547) | | $(51,967) | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.